期刊文献+

腺病毒介导miR-99a过表达抑制人结肠癌HCT-8细胞的生长抑制及其作用机制 被引量:3

Effect of adenovirus mediated overexpression of miR-99a on growth of human colon cancer HCT-8 cells and its mechanism
下载PDF
导出
摘要 目的探讨miR-99a过表达对人结肠癌HCT-8细胞的生长抑制及其作用机制。方法构建miR-99a的重组腺病毒Ad5-miR-99a,并感染人结肠癌HCT-8细胞。采用甲基化特异性PCR检测miR-99a、抑癌基因SOCS1和P16的甲基化水平;采用实时荧光定量PCR和Western Blot检测miR-99a、DNAC5胞嘧啶甲基转移酶、SOCS1和P16的表达情况;采用MTT法、细胞集落形成和流式细胞术检测HCT-8细胞的体外增殖凋亡情况;采用裸鼠体内荷瘤实验检测HCT-8细胞体内成瘤性。结果成功构建miR-99a腺病毒载体Ad5-miR-99a。Ad5-miR-99a感染HCT-8细胞后,Ad5-miR-99a组细胞中miR-99a表达显著高于空载腺病毒组和空白对照组(P<0.05),而其甲基化水平显著低于空载腺病毒组和空白对照组(P<0.05);Ad5-miR-99a组细胞中DNAC5胞嘧啶甲基转移酶表达显著低于空载腺病毒组和空白对照组(P<0.05);Ad5-miR-99a组细胞中SOCS1和P16表达显著高于空载腺病毒组和空白对照组(P<0.05),而其甲基化水平显著低于空载腺病毒组和空白对照组(P<0.05)。MTT法、细胞集落形成、流式细胞术和裸鼠体内荷瘤实验显示,Ad5-miR-99a组细胞的体外增殖和体内成瘤能力显著低于空载腺病毒组和空白对照组(P<0.05)。结论 miR-99a可显著抑制人结肠癌HCT-8细胞的体外增殖和体内成瘤能力,其机制可能与miR-99a过表达导致DNMT1表达升高,降低抑癌基因SOCS-1和P16甲基化程度,使得SOCS-1和P16高表达,从而发挥抑制肿瘤细胞生长的作用。 Objective To investigate the inhibitory effect of miR- 99 a overexpression on human colon cancer HCT- 8 cell line and its potential mechanism. Methods miR- 99 a recombinant adenovirus Ad5- miR- 99 a was constructed and to infect human colon cancer HCT-8 cells. The methylation levels of P16, SOCS1 and miR-99 a were detected by methylation specific PCR(MSP). The expressions of miR- 99 a, DNMT1, SOCS1 and P16 were inspected by real- time PCR and Western Blot. Proliferation and apoptosis of HCT- 8 cells were detected by MTT assay, cell colony formation and flow cytometry. In vivo tumor forming ability of HCT- 8cells were determined by nude mice. Results miR-99 a adenovirus vector Ad5-miR-99 a was successfully constructed. After infection, the expression of miR-99 a in Ad5-miR-99 a group was significantly higher than those in normal and control Ad-blank group(P〈0.05), and its methylation level was significantly lower than those of normal and control Ad-blank(P〈0.05). The expression of DNMT1 in Ad5-miR-99 a group was significantly lower than those in normal and control Ad-blank group(P〈0.05). The expressions of P16 and SOCS1 in Ad5- miR- 99 a group were significantly higher than those in normal and control Ad- blank group(P〈0.05),and the methylation levels were significantly lower than those in normal and control group(P〈0.05). MTT method, cell colony formation, flow cytometry and in vivo tumor forming ability experiments showed that the proliferation of Ad5- miR- 99 a cells in vitro and in vivo were significantly lower than those in Ad- blank and control normal group(P〈0.05). Conclusion Mi R- 99 a can significantly inhibit the proliferation of human colon cancer HCT-8 cells in vitro and in vivo. The mechanism may be related to the overexpression of miR-99 a, which leads to the increase of DNMT1 expression and decrease the level of tumor suppressor gene SOCS-1 and P16, which can inhibit the growth of tumor cells by SOCS-1 and P16.
出处 《兰州大学学报(医学版)》 CAS 2016年第3期22-28,共7页 Journal of Lanzhou University(Medical Sciences)
基金 重庆市卫生局医学科研项目(2012-2-291)
关键词 腺病毒 mir-99a 结肠癌 HCT-8细胞 作用机制 adenovirus mir-99a colon cancer HCT-8 cell mechanism of action
  • 相关文献

参考文献13

  • 1张伟华,郝丽萍.大肠癌的分子靶向治疗进展[J].兰州大学学报(医学版),2011,37(2):69-73. 被引量:5
  • 2Oberg A L, French A J, Sarver A L, et al. miRNA expres- sion in colon polyps provides evidence for a multihit model of colon cancer [J]. PLoS One, 2011; 6(6): e20465.
  • 3Toshinori H, Daniel J Weisenberger, Christopher P E. Genome-scale analysis of aberrant DNA methylation in colorectal cancer [J]. Genome Res, 2012, 22(2): 271-282.
  • 4Lin S Y, Yeh K T, Chen W T. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its rela- tionship to clinical features [J]. Oncol Rep, 2004, 11(2): 341-348.
  • 5张敬磊,金华君,刘辉,吕赛群,杨远,傅思源,钱其军,周伟平.腺病毒介导microRNA-99a过表达抑制肝癌细胞生长[J].中国肿瘤生物治疗杂志,2012,19(3):267-271. 被引量:4
  • 6Ambady S, Wu Z Y. Identification of novel microRNAs in xenopus laevis metaphase I1 arrested eggs [J]. Genesis, 2012, 50(3): 286-299.
  • 7Leu Y W, Rahmatpanah F, Shi H D. Double RNA interfer- ence of DNMT- 13b and DNMT- 1 enhances DNA demeth- ylation and gene reactivation [J]. Cancer Research, 2003, 63: 6110-6115.
  • 8Egwuagu C E, Yu C R, Zhang M F. Suppressors of cyto- kine signaling proteins are differentially expressed in Thl and Th2 cells: implications for Th Cell lineage commit- ment and maintenance [J]. J Immunol, 2002, 168(7): 3181-3187.
  • 9Du Y P, Peng J S, Sun A. Assessment of the effect of beta- ine on p16 and c-myc DNA methylation and mRNA ex- pression in a chemical induced rat liver cancer model [J]. BMC Cancer, 2009, 9: 261-270.
  • 10Mukhopadhyay P, Greene R M, Pisano M M. Cigarette smoke induces proteasomal-mediated degradation of DNA methyltransferases and methyl CpG-/CpG domain- binding proteins in embryonic orofacial cells [J]. Reprod Toxicol. 2015, 58: 140-148.

二级参考文献49

  • 1HURWITZ H, FEHRENBACHER L, NOVOTNY W, et al. Bevacizumab plus irinotecan, fluorouracil, and leu- covorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 350(23): 2335-2342.
  • 2CHARLES S, JOHN M, JOSE B. Randomized, con- trolled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study[J]. J Clin Oncol, 2008, 26(4): 689-690.
  • 3VAN E, RIVERA F, BERRY S, et al. Safety and efficacy of first-line bevacizumab with FOL- FOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study[J]. Ann Oncol, 2009, 20(11): 1842-1847.
  • 4WELCH S, KRZYZANOWSKA M, Moore M J, et al. Phase H study of capecitabine, irinotecan, and be- vacizumab (XELIRI-A) in patients with previously untreated metastatic colorectal cancer[J]. J Clin Oncol, 2009, 27(Suppl 15): 15 019.
  • 5WHYTE S, PANDOR A, STEVENSON M, et al. Be- vacizumab in combination with fiuoropyrimidine- based chemotherapy for the first-line treatment of metastatic colorectal cancer[J]. Health Technol As- sess, 2010, 14(2): 47-53.
  • 6KOZLOFF M, gators of the sociated with YOOD M, BERLIN J, et al. Investi- BRiTE study, clinical outcomes as- bevacizumab-containing treatment ofmetastatic colorectal cancer: the BRiTE observa- tional cohort study[J]. Oncologist, 2009, 14(9): 862- 870.
  • 7ALLEGRA C, YOTHERS G, CONNELL M, et al. Ini- tial safety report of NSABP C-08: a randomized phase m study of modified FOLFOX6 with or with- out bevacizumab for the adjuvant treatment of pa- tients with stage Ⅱ or Ⅲ colon cancer[J]. J Clin On- col, 2009, 27(20): 3385-3 390.
  • 8SALTZ L B, MEROPOL N J, LOEHRER P J, et al. Phase ]I trial of cetuximab in patients with refrac-tory colorectal cancer that expresses the epidermal growth factor receptor[J]. J Clin Oncol, 2004, 22(7): 1 201-1 208.
  • 9VENOOK A, NIEDZWIECKI D, HOLLIS D, et al. Phase Ⅲ study of irinotecan/5FU/LV (FOLFIRI)or oxaliplatin/5FU/LV (FOLFOX)-+-cetuximab for pa- tients with untreated metastatic adenocarcinoma ofthe colon or rectum (MCRC): CALGB 80203 pre- liminary results[J]. Journal of Clinical Oncology, 2006, 24(Suppl 18): 3 509.
  • 10RAOUL J L, Van LAETHEM J L, PEETERS M, et al. Cetuximab in combination with irinotecan/5- fluorouracil/folinic acid (FOLFIRI) in the initialtreatment of metastatic colorectal cancer: a multi-centre two-part phase I / II study[J]. BMC Cancer, 2009, 14(9): 112.

共引文献7

同被引文献11

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部